American Bio Medica Corporation
ABMC · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | 0.07 | 0.08 |
| FCF Yield | -42.82% | -231.16% | -8.21% | -7.90% |
| EV / EBITDA | 0.50 | -9.39 | -10.17 | -7.27 |
| Quality | ||||
| ROIC | 74.91% | 1,254.55% | 66.50% | 219.62% |
| Gross Margin | 45.12% | -83.83% | -4.31% | -39.46% |
| Cash Conversion Ratio | -0.19 | 1.93 | 0.24 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -43.33% | -39.64% | -33.43% | -26.99% |
| Free Cash Flow Growth | 40.59% | -714.67% | -8.70% | -430.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | -8.39 | -6.50 | -4.65 |
| Interest Coverage | -10.10 | -30.29 | -4.94 | -6.67 |
| Efficiency | ||||
| Inventory Turnover | 0.92 | 0.81 | 0.57 | 0.64 |
| Cash Conversion Cycle | -425.16 | 41.36 | -131.54 | -30.19 |